Table 2. Medication Use on Discharge. | |||
Medication |
PCI Group (N = 1071) |
Medical Therapy Group (N = 1078) |
P Value |
Aspirin — no. (%) |
1037 (97) |
1015 (94) |
0.003 |
Clopidogrel — no. (%) |
789 (74) |
258 (24) |
<0.001 |
Ticlopidine — no. (%) |
189 (18) |
60 (6) |
<0.001 |
Thienopyridine (clopidogrel or ticlopidine) — no. (%)1 |
974 (91) |
317 (29) |
<0.001 |
Aspirin or thienopyridine — no. (%) |
1066 (100) |
1047 (97) |
<0.001 |
Aspirin plus thienopyridine — no. (%)1 |
945 (88) |
285 (26) |
<0.001 |
Warfarin — no. (%) |
76 (7) |
135 (13) |
<0.001 |
One or morę of the following: aspirin, warfarin, or thienopyridine — no. (%) |
1068 (100) |
1068 (99) |
0.09 |
Two or morę of the following: aspirin, warfarin, or thienopyridine — no. (%) |
962 (90) |
378 (35) |
<0.001 |
Beta-blocker— no. (%) |
925 (86) |
961 (89) |
0.05 |
Calcium-channel blocker— no. (%) |
65 (6) |
61 (6) |
0.69 |
Long-acting nitrate— no. (%) |
202 (19) |
283 (26) |
<0.001 |
Angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker — no. (%) |
860 (80) |
866 (80) |
0.98 |
In patients with an ejection fraction of <40% — no./ total no. (%) |
209/229 (91) |
190/205 (93) |
0.59 |
Diuretic agent— no. (%) |
173 (16) |
183 (17) |
0.57 |
Digoxin — no. (%) |
33 (3) |
26 (2) |
0.34 |
Spironolactone— no. (%) |
50 (5) |
65 (6) |
0.16 |
Insulin — no. (%) |
66 (6) |
63 (6) |
0.76 |
Orał hypoglycemic agent — no. (%) |
124 (12) |
168 (16) |
0.01 |
Lipid-lowering agent — no. (%) |
858 (80) |
884 (82) |
0.26 |
A thienopyridine was prescribed for morę than 99% of the patients, and aspirin plus a thienopyridine for 97% of those in the PCI group in whom PCI with stenting was successful.